Compare Marsh & McLennan Companies, Inc. (MRSH) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Novavax Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $175.76 (market cap $84.31B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 46.3× Novavax Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and Novavax Inc for 59 Days on average.
| MRSH | NVAX | |
|---|---|---|
Market Cap | $84.31B | $1.82B |
Volume | 3,948,947 | 6,198,505 |
Sector | Financials | Health |
52-Week High | $207.02 | $12.75 |
52-Week Low | $157.32 | $6.22 |
Typical Hold Time | 109 Days | 59 Days |
Enterprise Value | $104.99B | $1.39B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $176.67, up 1.73% today, with a bullish technical trend and strong support at $174. The company shows robust fundamentals, with revenue growing to $26.98B in 2025 and a net income margin of 14.24%. Recent acquisition of Accel Holdings (Business Wire, 2026-10-02) may enhance growth. Earnings have consistently beaten estimates in recent quarters, with Q3 2026 results pending.
Outlook is positive with a consensus price target of $202.71 (MarketBeat, 2026-09-30), offering ~15% upside. Risks include competitive pressures and market volatility. Analyst sentiment is mixed, with 32% buy ratings but 65% hold, suggesting cautious optimism amid solid execution.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
